![Natasha Hernday](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Natasha Hernday
Director/Board Member at
JANUX THERAPEUTICS, INC.
Net worth: 95 708 $ as of 30/06/2026
Profile
Natasha A. Hernday is currently an Independent Director at Janux Therapeutics, Inc. since 2024.
Former positions include Director-Mergers, Acquisitions & Out-Partnering at Amgen, Inc. from 1994 to 2010; Independent Director at PDL BioPharma, Inc. from 2019 to 2022; Independent Director at Alpine Immune Sciences, Inc. from 2020 to 2024; Independent Director at XOMA Royalty Corp.
from 2020 to 2026; and Chief Business Officer at Seagen, Inc. from 2022 to 2023.
Education includes an MBA from Pepperdine University and an undergraduate degree from the University of California, Santa Barbara.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 11/06/2026 | 6,231 ( 0.01% ) | 95 708 $ | 30/06/2026 |
Natasha Hernday active positions
| Companies | Position | Start |
|---|---|---|
| JANUX THERAPEUTICS, INC. | Director/Board Member | 19/07/2024 |
Former positions of Natasha Hernday
| Companies | Position | End |
|---|---|---|
| XOMA ROYALTY CORPORATION | Director/Board Member | 14/07/2026 |
| ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 20/05/2024 |
| SEAGEN INC. | Corporate Officer/Principal | 01/01/2023 |
| PDL BIOPHARMA, INC. | Director/Board Member | 01/12/2022 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2010 |
Training of Natasha Hernday
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
87
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
XOMA Royalty Corp.
 XOMA Royalty Corp. Pharmaceuticals: MajorHealth Technology Discovers and develops antibody therapeutics | Health Technology |
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Pepperdine University
 Pepperdine University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that manufactures and wholesales prescription medicine products | Health Technology |
Alpine Immune Sciences, Inc.
 Alpine Immune Sciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as an bio pharmaceutical company that develops immunotherapies for autoimmune and inflammatory diseases | Health Technology |
Janux Therapeutics, Inc.
 Janux Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage company that develops precision engineered immunotherapies | Health Technology |
- Stock Market
- Insiders
- Natasha Hernday
